<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02848742</url>
  </required_header>
  <id_info>
    <org_study_id>R2-16-001</org_study_id>
    <nct_id>NCT02848742</nct_id>
  </id_info>
  <brief_title>Dermal Cryotherapy for Treatment of Pigmented Lesions</brief_title>
  <official_title>Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R2 Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>R2 Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the ability of the Dermal Cooling System to reduce pigmentation in benign&#xD;
      pigmented lesions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, non-randomized, multi-center study of the Dermal Cooling System&#xD;
      to verify that the device causes a reduction in pigmentation in benign pigmented lesions, and&#xD;
      to determine at what parameters the device is most effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">March 2020</completion_date>
  <primary_completion_date type="Actual">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of pigmentation in treated lesions</measure>
    <time_frame>90 days</time_frame>
    <description>Changes in pigmentation graded using a 4-point standardized scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of device- or procedure-related adverse events</measure>
    <time_frame>0 to 12 months</time_frame>
    <description>Side effects, discomfort assessments both during treatment and follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Pigmented Skin Lesion</condition>
  <arm_group>
    <arm_group_label>Treatment with cryotherapy device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To include subjects with one or more benign pigmented lesions who are willing to have the pigmented skin exposed to cooling with the Dermal Cooling System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dermal Cooling System</intervention_name>
    <description>Dermal cryotherapy</description>
    <arm_group_label>Treatment with cryotherapy device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects &gt; 18 years of age.&#xD;
&#xD;
          2. Subject has one or more benign pigmented lesions (e.g., solar lentigines, melasma,&#xD;
             freckles, caf√© au lait, nevi, or hyperpigmentation), in an area suitable for treatment&#xD;
&#xD;
          3. Subject is willing to have up to 40 treatment sites and/or an area up to 8 square&#xD;
             inches treated depending on the size and nature of the lesions identified.&#xD;
&#xD;
          4. Subject is willing to have digital photographs taken of the treatment area and agrees&#xD;
             to use of photographs for presentation, educational, or marketing purposes.&#xD;
&#xD;
          5. Subject is willing to cover treated area or have very limited sun exposure and use an&#xD;
             approved sunscreen of SPF 50 or higher on the treated areas for the duration of the&#xD;
             study, including the follow-up period, if requested.&#xD;
&#xD;
          6. Subject has read and signed a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Physician prescribed medical or surgical treatment, or use of over-the-counter&#xD;
             products to alter skin color, in the area of intended treatment in the previous 6&#xD;
             months (e.g., hydroquinone, corticosteroids, laser surgery)&#xD;
&#xD;
          2. Artificial tanning in the area of intended treatment within 1 month (e.g., spray,&#xD;
             lotion, tanning bed) or intention to use artificial tanning within the follow-up&#xD;
             period&#xD;
&#xD;
          3. Scars or tattoos in the location of the treatment sites&#xD;
&#xD;
          4. History of vitiligo, eczema, or psoriasis in the area of treatment&#xD;
&#xD;
          5. History of melanoma&#xD;
&#xD;
          6. Known history of illness or adverse reaction to cold insult (e.g., cryoglobulinemia,&#xD;
             cold urticaria, paroxysmal cold hemoglobinuria, Reynaud's disease.&#xD;
&#xD;
          7. History of abnormal wound healing or abnormal scarring&#xD;
&#xD;
          8. Inability or unwillingness to comply with the study requirements.&#xD;
&#xD;
          9. Current enrollment in a clinical study of any other unapproved investigational drug or&#xD;
             device.&#xD;
&#xD;
         10. Any other condition or laboratory value that would, in the professional opinion of the&#xD;
             investigator, potentially affect response or participation in this clinical study, or&#xD;
             would pose an unacceptable risk to the subject.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristine Tatsutani, PhD</last_name>
    <role>Study Director</role>
    <affiliation>R2 Dermatology, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diablo Clinical Research</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arbutus Laser Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6J 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 26, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pigmentation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

